Orenitram (treprostinil) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: ______

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:		

MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
DURATION OF THERAPY (SPE	RENEWAL CIFIC DATES):	IF RENEWAL: DATE THERAPY INITIATED:		

Continued on next page.



Orenitram (treprostinil) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 🗌 NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
 Pulmonary arterial hypertension (PAH) Other diagnosis: 	ICD-10:			
3. REQUIRED CLINICAL INFORMATION: PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information: Is the prescribing physician a specialist in one of the following fields: pulmonology, cardiology, nephrology, or rheumatology? Yes No Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) WHO Group 1? Yes No Please				
provide documentation.				
 Select if the patient has the following causes for pulmonary arterial hypertension (PAH): Idiopathic/primary PAH Drugs and toxins induced(not reactive to acute vasoreactivity testing (AVT) or failed calcium channel blocker)CCB treatment) Connective tissue disease (e.g., Lupus/SLE, RA, scleroderma, systemic sclerosis, CREST syndrome, polymyositis, polyarteritis nodosa, mixed connective tissue disease) HIV infection Portal hypertension Congenital heart disease (e.g., atrial septal defect) Schistosomiasis Associated with surgical repair of a congenital systemic-to-pulmonary shunt of at least 1year in duration (e.g., ventricular septal defect, patent ductus arteriosus) Chronic hemolytic anemia 				
Is patient WHO functional class II thru IV? Yes No please provide documentation.				
Does patient have a mean pulmonary artery pressure (mPAP) equaling 25 mmHg or greater? Yes No Please provide cardiac catheterization report.				
Does patient have a pulmonary capillary wedge pressure (PCWP) equaling 15 mmHg or less? Yes No Please provide cardiac catheterization report.				
Does patient have a pulmonary vascular resistance (PVR) equaling 3 Wood units via right heart cath or greater? □ Yes □ No Please provide cardiac catheterization report.				



Orenitram (treprostinil) Prior Authorization Request Form Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Does patient have a history of left-sided heart disease?

Yes
No

Does patient have severe renal insufficiency?

Yes
No please provide documentation.

Has patient had an inadequate response or intolerance to a PDE5 inhibitor such as Revatio(sildenafil and/or Adcirca(tadalafil)?
Yes
No Please provide documentation.

Does patient have contraindications to PDE5 inhibitors Revatio(sildenafil and/or Adcirca(tadalafil)?

Yes
No

Has patient had an inadequate response or intolerance to Adempas (riociguat) ? Yes
No Please provide documentation.

Does patient have contraindications to Adempas (riociguat)?
Yes
No Please provide documentation.

Has patient had an inadequate response or intolerance to an endothelin receptor antagonist [e.g., Letairis (ambrisentan), Opsumit (macitentan), or Tracleer (bosentan)]?
Ves
No Please provide documentation.

Does patient have contraindications to an endothelin receptor antagonist [e.g., Letairis (ambrisentan), Opsumit (macitentan), or Tracleer (bosentan)]?
Ves
No Please provide documentation.

Will Orenitram(treprostinil) be taken in combination with a prostanoid/prostacyclin analogue (e.g., epoprostenol, iloprost, treprostinil, and/or selexipag)?
Yes
No Please provide documentation.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811

